These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27990792)

  • 1. Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne.
    Kosmidou M; Milionis H
    Minerva Endocrinol; 2017 Jun; 42(2):109-121. PubMed ID: 27990792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
    Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
    J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study - sample of São José do Rio Preto.
    Andrade GC; Fujise LH; Santana JE; Oliveira F; Silva Rde C
    Rev Assoc Med Bras (1992); 2016; 62(3):218-26. PubMed ID: 27310544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic Fatty Liver Disease.
    Sweet PH; Khoo T; Nguyen S
    Prim Care; 2017 Dec; 44(4):599-607. PubMed ID: 29132522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steatosis and NASH in type 2 diabetes.
    Hu M; Phan F; Bourron O; Ferré P; Foufelle F
    Biochimie; 2017 Dec; 143():37-41. PubMed ID: 29097281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological management of nonalcoholic fatty liver disease.
    Barb D; Portillo-Sanchez P; Cusi K
    Metabolism; 2016 Aug; 65(8):1183-95. PubMed ID: 27301803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.
    Lee BW; Lee YH; Park CY; Rhee EJ; Lee WY; Kim NH; Choi KM; Park KG; Choi YK; Cha BS; Lee DH;
    Diabetes Metab J; 2020 Jun; 44(3):382-401. PubMed ID: 32431115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    Seto WK; Yuen MF
    J Gastroenterol; 2017 Feb; 52(2):164-174. PubMed ID: 27637587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-alcoholic fatty liver disease (NAFLD)].
    Rau M; Weiss J; Geier A
    Dtsch Med Wochenschr; 2015 Jul; 140(14):1051-5. PubMed ID: 26182253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transplantation and non-alcoholic fatty liver disease.
    Zezos P; Renner EL
    World J Gastroenterol; 2014 Nov; 20(42):15532-8. PubMed ID: 25400437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.
    Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Targher G; Lonardo A
    Int J Mol Sci; 2016 Mar; 17(3):355. PubMed ID: 27005620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: A cross-sectional study in north of Iran.
    Mansour-Ghanaei F; Joukar F; Mobaraki SN; Mavaddati S; Hassanipour S; Sepehrimanesh M
    Diabetes Metab Syndr; 2019; 13(2):1591-1596. PubMed ID: 31336526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathogenesis of non-alcoholic fatty liver disease].
    Anty R; Gual P
    Presse Med; 2019 Dec; 48(12):1468-1483. PubMed ID: 31767252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
    Lonardo A; Lugari S; Ballestri S; Nascimbeni F; Baldelli E; Maurantonio M
    Acta Diabetol; 2019 Apr; 56(4):385-396. PubMed ID: 30519965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD).
    Alwahsh SM; Gebhardt R
    Arch Toxicol; 2017 Apr; 91(4):1545-1563. PubMed ID: 27995280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.